Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive Disorder
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
UBS Remains Sidelined on Alkermes plc (ALKS) Following Failed ALKS 5461 Studies
January 22, 2016 9:40 AM ESTUBS maintained a Neutral rating on Alkermes (NASDAQ: ALKS), and cut the price target to $36.00 (from $65.00). With the failure of FORWARD-3 and FORWARD-4 studies for ALKS 5461 in MDD, UBS believes that there is a very low possibility of getting this product approved even... More
Morgan Stanley Downgrades Alkermes (ALKS) to Underweight
January 21, 2016 12:52 PM ESTMorgan Stanley downgraded Alkermes (NASDAQ: ALKS) from Overweight to Underweight with a price target of $35.00.
For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.
Shares of Alkermes closed at $60.42 yesterday.
... MoreAlkermes (ALKS) PT Cut to $58 at Leerink Partners; Maintains 'Outperform'
January 21, 2016 10:07 AM ESTLeerink Partners analyst Paul Matteis lowered his price target on Alkermes (NASDAQ: ALKS) to $58.00 (from $84.00) after the company released news on two of its Phase 3 programs for ALKS5461 missing their primary endpoints (PEs). The firm maintained an Outperform rating.
Matteis commented, ". While the... More
Cowen Downgrades Alkermes (ALKS) to Market Perform
January 21, 2016 9:51 AM ESTCowen downgraded Alkermes (NASDAQ: ALKS) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.
Shares of Alkermes closed at $60.42 yesterday.
... More